Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

StatusWithdrawn
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Withdrawn before enrolling Sponsor's reason: study halted prematurely prior to enrollment of first participant Show 5 more changesShow less
    • Enrollment target: estimated 116 to confirmed 0
    • Study sites: 2 to 0
    • Eligibility criteria expanded, about 37 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Start date: Jul 1, 2026 to Dec 1, 2026
    • Site contacts updated at 2 of 2 sites
    v3
  3. Start date: May 1, 2026 to Jul 1, 2026v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-associated oropharyngeal (tongue base or tonsil) squamous cell carcinoma,.
Trial Details
NCT Number NCT07513324
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Related terms Squamous Cell Carcinoma of Head and Neck
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov